載入中
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
前收盤價
US$28.51
+US$0.78 · +2.81%
盤中時間採用ET。市場資料可能有所延遲。
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
日內區間
目前US$28.51
52週區間
目前US$28.51
盤中時間採用ET。市場資料可能有所延遲。
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
日內區間
目前US$28.51
52週區間
目前US$28.51
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 43.1萬 USD | — | — | — | — |
| 毛利 | −43.1萬 USD | — | — | — | — |
| 研究與開發 | 3.45億 USD | 1.02億 USD | 6380.6萬 USD | 5423.4萬 USD | 4498.1萬 USD |
| 銷售、一般及管理費用 | 4838.7萬 USD | 4927.7萬 USD | 3702.1萬 USD | 1612.1萬 USD | 1070.1萬 USD |
| 營業費用 | 3.93億 USD | 1.51億 USD | 1.01億 USD | 7035.5萬 USD | 5568.2萬 USD |
| 利息收入 | 3370.4萬 USD | 4094萬 USD | 1502萬 USD | 158.9萬 USD | 70.3萬 USD |
| 利息支出 | — | 9.4萬 USD | 8.8萬 USD | 5.9萬 USD | 1.8萬 USD |
| 折舊和攤銷 | 43.1萬 USD | 34.6萬 USD | 29.2萬 USD | 29.1萬 USD | 29.6萬 USD |
| 營業利益 | −3.93億 USD | −1.51億 USD | −1.01億 USD | −7035.5萬 USD | −5568.2萬 USD |
| 淨利 | −3.6億 USD | −1.1億 USD | −8589.5萬 USD | −6886.7萬 USD | −5499萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$97.80
上漲空間 243.04%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.15億0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI9680.94萬0.98%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap ETFVB8314.12萬0.04%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK4785.4萬0.10%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF4427.72萬0.05%954億 USD0.05%US$235+0.80%
Schwab U.S. Small-Cap ETFSCHA1828.41萬0.08%218.24億 USD0.03%US$32.79+0.40%
iShares Russell Mid-Cap ETFIWR1394.71萬0.02%567.65億 USD0.18%US$109.82+0.87%
Vanguard Health Care ETFVHT1101.58萬0.05%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell Mid-Cap ETFIWRVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
